ArticleCureus2025
Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression and Its Correlation With Clinicopathological Parameters in Oral Squamous Cell Carcinoma: A Tertiary Care Center Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction This study endeavors to evaluate the frequency of programmed death-ligand 1 (PD-L1) expression in oral squamous cell carcinoma (OSCC) specimens and to correlate these findings with clinicopathological features of established prognostic significance. Methodology The study included paired pre-surgical biopsy and resection specimens from 35 patients with OSCC. Immunohistochemistry was performed for PD-L1 (clone SP263) with 51.4% tumor proportion score (TPS) and 77.1% combined proportion score (CPS), which was assessed at a cut-off of ≥1%. The association of the mean expression of the biomarker with clinicopathological parameters has been evaluated. Results TPS of PD-L1 expression at the cut-offs of ≥1%, ≥10%, ≥25%, and ≥50%, and the positivity rates were 20% (7/35), 8.6% (3/35), 8.6% (3/35), and 14.3% (5/35), respectively. The CPS at the same cut-offs were 22.9%, 31.4%, 17.1%, 11.4%, and 17.1%, respectively. TPS was significantly correlated with stage (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.